Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Albanell

Showing results (31-40 of 93) with videos related to

Pageof 10
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.
Cancer|February 1, 1995
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancerL A Solé, J Albanell, J Bellmunt, et al.
Cancer Research|June 19, 2001
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsM A Molina, J Codony-Servat, J Albanell, et al.
Medical and Pediatric Oncology|January 1, 1992
Interferon and disseminated Langerhans cell histiocytosisJ Bellmunt, J Albanell, A Salud, et al.
Revista Clinica Espanola|May 1, 1992
[Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]J Albanell, O S Gallego, J Bellmunt, et al.
Radiologia|August 4, 2009
[Breast MRI: the usefulness of diffusion-weighted sequences for differentiating between benign and malignant lesions]J Barceló, J C Vilanova, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 3, 2007
Sorafenib TARGET trial results in Spanish patientsJ Bellmunt, J L González-Larriba, M A Climent, et al.
Differentiation; Research in Biological Diversity|August 1, 1997
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganizationK Nason-Burchenal, W Maerz, J Albanell, et al.
Cancer Research|April 1, 1996
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell linesJ Albanell, W Han, B Mellado, et al.
Journal of the National Cancer Institute|August 5, 1999
Telomerase activity in germ cell cancers and mature teratomasJ Albanell, G J Bosl, V E Reuter, et al.
Pageof 10

Showing results (31-40 of 93) with videos related to

Sort By:
Pageof 10
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 17, 1998
PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent mannerM Bos, J Mendelsohn, Y M Kim, et al.
Cancer|February 1, 1995
Phase II trial of an all-oral regimen of tegafur and folinic acid in patients with previously treated metastatic breast cancerL A Solé, J Albanell, J Bellmunt, et al.
Cancer Research|June 19, 2001
Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsM A Molina, J Codony-Servat, J Albanell, et al.
Medical and Pediatric Oncology|January 1, 1992
Interferon and disseminated Langerhans cell histiocytosisJ Bellmunt, J Albanell, A Salud, et al.
Revista Clinica Espanola|May 1, 1992
[Bladder neoplasm in a patient with panarteritis nodosa treated with cyclophosphamide]J Albanell, O S Gallego, J Bellmunt, et al.
Radiologia|August 4, 2009
[Breast MRI: the usefulness of diffusion-weighted sequences for differentiating between benign and malignant lesions]J Barceló, J C Vilanova, J Albanell, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|November 3, 2007
Sorafenib TARGET trial results in Spanish patientsJ Bellmunt, J L González-Larriba, M A Climent, et al.
Differentiation; Research in Biological Diversity|August 1, 1997
Common defects of different retinoic acid resistant promyelocytic leukemia cells are persistent telomerase activity and nuclear body disorganizationK Nason-Burchenal, W Maerz, J Albanell, et al.
Cancer Research|April 1, 1996
Telomerase activity is repressed during differentiation of maturation-sensitive but not resistant human tumor cell linesJ Albanell, W Han, B Mellado, et al.
Journal of the National Cancer Institute|August 5, 1999
Telomerase activity in germ cell cancers and mature teratomasJ Albanell, G J Bosl, V E Reuter, et al.
Pageof 10